Empower your patients to break free from HAE

Running Tennis Woman Shards of Glass

Empower your patients to break free from HAE

Running Tennis Woman Shards of Glass
with the only c1-inh subcutaneous injection FOR THE PREVENTION OF HAE ATTACKS

*Median reduction in number of attacks with HAEGARDA vs placebo. In a 32-week crossover study, patients ≥12 years of age with symptomatic type 1 or 2 HAE (N=90) were randomly assigned to twice-weekly therapy with HAEGARDA 40 IU/kg or 60 IU/kg. Patients initiated 16 weeks of active therapy or placebo and crossed over to placebo or active therapy for the subsequent 16 weeks. Baseline HAE attack frequency was 8.8 in the 3 months before screening for the 60 IU/kg group.1

99% less rescue medication with HAEGARDA 60 IU/kg vs placebo (median)

taking haegarda reduced the use of rescue medication by >99%‡§1

The WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times.2 §Median reduction in rescue medication use vs placebo.

Subcutaneous C1‑INH builds and maintains steady-state C1-INH functional activity3

Functional C1-INH level. Relative risk for an HAE attack.

safety and tolerability

Adverse reactions occurring in >4% of patients while taking HAEGARDA

  • 1 patient discontinued HAEGARDA because of a treatment-related adverse reaction (urticaria)1

||Includes patients who were treated with 40 IU/kg and 60 IU/kg. Includes bruising, coldness, discharge, erythema, hematoma, hemorrhage, induration, edema, pain, pruritus, rash, injection-site reaction, scarring, swelling, urticaria, and warmth at the injection site. #Includes hypersensitivity, pruritus, rash, and urticaria.


The only C1‑INH subcutaneous therapy for prevention of HAE attacks

HAEGARDA can be administered in any applicable subcutaneous injection site.

Support and financial assistance with


Support available from 8 AM to 8 PM ET, 1-844-HAEGARDA (1-844-423-4273)

You are now leaving the current website.